

PharmaNutra was exhibiting at CPhI Worldwide 2019 in Frankfurt

CPhI Worldwide 2019 was held from 5th to 7th November: three days dedicated to the best of global pharma, during which PharmaNutra S.p.A. presented its more recent scientific novelties to international partners.

Pisa, 8th November 2019 – The thirtieth edition of CPhI Worldwide, the pharmaceutical sector's most important international fair, ended yesterday after bringing together 45,000 participants. The most important exhibitors included PharmaNutra S.p.A. (Aim Italia - Ticker PHN), the pharmaceutical company leader in the oral iron-based products sector, due to the well-acknowledged effectiveness of the Sucrosomial® Technology.

Exhibiting for the second time, PharmaNutra reaped considerable success in terms of visibility and people visiting the stand; consistent with the fair's growth trend - in both participation and importance - as it represents the best of the entire pharmaceutical production chain.

Present in Germany, the President of PharmaNutra S.p.A. Andrea Lacorte, the COO, Carlo Volpi and the Chief Scientific Officer, Germano Tarantino, together with the R&D team and the Group's foreign department.

"CPhI is a very important event. It not only creates an opportunity to establish business contacts with companies and professional from all over the world, but is also useful for meeting our foreign partners. Compared to our first time exhibiting, in 2018, during this edition we undoubtedly found that the company's reputation is growing. We are already present successfully in more than 50 countries which is definitely an indicator of reliability", comments the President, Andrea Lacorte.

"We have several foreign market objectives, both short and medium-long term", declares the Group's COO, Carlo Volpi. "On the one hand, all the partners we are collaborating with are growing with the current product portfolio. The next step will be to expand the commercial offer in single Countries, starting with Cetilar®, ApportAL® and UltraMag®. On the other, between 2020 and the start of 2021, commercialisation will be starting in all the Countries with which we have recently signed distribution agreements. In addition to collaboration following contacts started during this CPhI 2019. We expect to end the year with significant growth and for that to continue over the next few years".

From the scientific development point of view, during the three CPhI 2019 days the Group's R&D department presented the results of new research on both of the company's flagship lines. *"For Cetilar®, we have recently published a study on professional athletes, focussed in a daily combined*

use of Cetilar® Cream and Cetilar® Patch during the rehabilitation stage. For SiderAL®, we have presented evidence on the basic research and action mechanism of Sucrosomial® Iron, together with the clinical studies discussed during the last IMCID (International Multidisciplinary Course on Iron Deficiency) held in Rome last March”, says **Germano Tarantino, Chief Scientific Officer of PharmaNutra.**

A highly positive outcome enabling the company to focus on the next events in 2020, **anticipated by the President, Lacorte:** “From 12th to 14th May we will be returning to Vitafoods Europe in Geneva. Then we will be concentrating on CPhI Worldwide 2020, to be held from 13th to 15th October in Milan: playing on home ground we cannot but hope to have an even more prestigious event space”.

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated by numerous clinical studies, 91 of them published and with more than 6000 subjects treated with the supplements. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 140 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 34 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

<http://www.PharmaNutra.it>

For Information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
Fax +39 050 7846524
investorrelation@pharmanutra.it

Nomad & Specialist

CFO SIM S.p.A.
Via dell'Annunciata
23/4
20121 Milan
Tel. +39 02 303431
ecm@cfosim.com

Press Office

Spriano Communication&Partners
Tel. +39 02 83635708
Matteo Russo
Mob. +39 347 9834881
mrusso@sprianocommunication.com
Cristina Tronconi
Mob. +39 346 0477901
ctronconi@sprianocommunication.com